825 related articles for article (PubMed ID: 34048680)
21. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
22. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].
Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T
Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293
[TBL] [Abstract][Full Text] [Related]
23. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Johnson P; Federico M; Kirkwood A; Fosså A; Berkahn L; Carella A; d'Amore F; Enblad G; Franceschetto A; Fulham M; Luminari S; O'Doherty M; Patrick P; Roberts T; Sidra G; Stevens L; Smith P; Trotman J; Viney Z; Radford J; Barrington S
N Engl J Med; 2016 Jun; 374(25):2419-29. PubMed ID: 27332902
[TBL] [Abstract][Full Text] [Related]
24. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Anderson RA; Remedios R; Kirkwood AA; Patrick P; Stevens L; Clifton-Hadley L; Roberts T; Hatton C; Kalakonda N; Milligan DW; McKay P; Rowntree C; Scott FM; Johnson PWM
Lancet Oncol; 2018 Oct; 19(10):1328-1337. PubMed ID: 30220622
[TBL] [Abstract][Full Text] [Related]
25. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
Phillips T; Migliaccio-Walle K; Yu KS; Bloudek B; Liu N; Fanale M; Burke JM
Leuk Lymphoma; 2023 May; 64(5):1017-1025. PubMed ID: 37074674
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ;
Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416
[TBL] [Abstract][Full Text] [Related]
27. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
28. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
29. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA
J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569
[TBL] [Abstract][Full Text] [Related]
30. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857
[TBL] [Abstract][Full Text] [Related]
31. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
[TBL] [Abstract][Full Text] [Related]
32. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
[TBL] [Abstract][Full Text] [Related]
33. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A
J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753
[TBL] [Abstract][Full Text] [Related]
34. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Kumar A; Casulo C; Yahalom J; Schöder H; Barr PM; Caron P; Chiu A; Constine LS; Drullinsky P; Friedberg JW; Gerecitano JF; Hamilton A; Hamlin PA; Horwitz SM; Jacob AG; Matasar MJ; McArthur GN; McCall SJ; Moskowitz AJ; Noy A; Palomba ML; Portlock CS; Straus DJ; VanderEls N; Verwys SL; Yang J; Younes A; Zelenetz AD; Zhang Z; Moskowitz CH
Blood; 2016 Sep; 128(11):1458-64. PubMed ID: 27458003
[TBL] [Abstract][Full Text] [Related]
36. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
[TBL] [Abstract][Full Text] [Related]
37. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Russell J; Collins A; Fowler A; Karanth M; Saha C; Docherty S; Padayatty J; Maw K; Lentell I; Cooke L; Hodson A; Shah N; Sadullah S; Grigoropoulos N; Qian W; Kirkwood AA; Uttenthal BJ; Johnson P; Follows GA
Ann Hematol; 2021 Apr; 100(4):1049-1058. PubMed ID: 33641019
[TBL] [Abstract][Full Text] [Related]
38. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
[TBL] [Abstract][Full Text] [Related]
39. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
[TBL] [Abstract][Full Text] [Related]
40. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
